Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PharmAbcine Signs CMO Contract with Binex | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

PharmAbcine Signs CMO Contract with Binex

CDMO Binex to produce olinvacimab at its new 5,000L production line.

By: Contract Pharma

Contract Pharma Staff

PharmAbcine, a biotech company focusing on the development of antibody therapeutics, has signed a contract manufacturing organization(CMO) agreement with Binex, a biologics contract development and manufacturing organization (CDMO) company in Korea.
 
With the new contract, Binex will produce Olinvacimab (TTAC-0001), PharmAbcine’s leading antibody therapeutics pipeline in oncology, using the new 5,000L production line while it was previously produced in the 1,000L production line. This contract will allow Binex to start the operation of its new 5,000L production line designed for large-scale commercial production.
 
As for PharmAbcine, this agreement will accommodate more timely and less costly delivery of Olinvacimab for its rapidly expanding list of both clinical and non-clinical studies. The list of studies includes, among others, the global clinical trial for Avastin refractory rGBM(recurrent glioblastoma multiforme) patients, the global combination trial with pembrolizumab for mTNBC(metastatic triple negative breast cancer), the research collaboration with SLBio in China for non-small cell lung cancer therapeutics, multiple investigator-initiated studies planned for solid tumors, etc.
 
“We are very pleased with this agreement as Binex has been a very reliable clinical manufacturing partner since the very beginning of the clinical trials,” said Jin-San Yoo, chief executive officer, PharmAbcine. “This agreement bodes well with our business strategy of aggressively expanding the indications of our front runner molecule.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics